Kratom industry warns synthetic opioids should not be called 'kratom', tell me about this news today

The recent warnings from the kratom industry and public health officials center on the proliferation of potent, lab-synthesized or hyper-concentrated opioid compounds that are being deceptively packaged and sold under the label “kratom.”

Key Details of the Warning

• The Core Distinction: Natural kratom is derived from the dried leaves of Mitragyna speciosa, a Southeast Asian tree that naturally contains small amounts of alkaloids such as mitragynine and trace quantities of 7-hydroxymitragynine (7-OH). Advocacy groups and traditional kratom manufacturers argue that isolated, chemically modified, or synthetically synthesized compounds should not be called or marketed as botanical kratom.

  Business Today+ 1

• Emergence of Synthetic and Concentrated Derivatives: The warning targets synthetic products and high-potency formulationsparticularly mass-produced 7-OH tablets, liquid shots, and other synthetic analogues (such as mitragynine pseudoindoxyl, MGM-15, and MGM-16). Because 7-OH appears only in trace amounts in the natural leaf, the high-potency versions found in smoke shops and gas stations are often synthesized or chemically concentrated in laboratories rather than being raw herbal extracts.

  WQAD+ 1

• Safety and Addiction Concerns: Public health agencies and medical specialists caution that these concentrated products act as potent mu-opioid receptor agonists, carrying severe risks of rapid physical dependence, addiction, respiratory depression, and overdosefar exceeding the effects of traditional whole-leaf kratom powder or tea.

  WQAD

• The Industry’s Motivation: Mainstream kratom advocates (such as the American Kratom Association) are actively distancing the botanical plant from these synthetic products. Their concern is that adverse events, hospitalizations, or fatalities caused by synthetic compounds misbranded as “kratom” will trigger blanket bans on the natural plant, rather than targeted restrictions on dangerous synthetic opioids.

  WQAD

• Regulatory and Law Enforcement Response: Regulators and law enforcement have stepped in:

  • The DEA has pursued temporary Schedule I placement for high-threshold 7-OH and specific synthetic variants, aiming to distinguish these potent drugs from standard botanical kratom leaf products.

    Business Today

  • Several individual states have introduced emergency bans or restrictions classifying isolated/synthetic kratom derivatives as controlled dangerous substances.

    Business Today

  • The FDA continues to issue warning letters against manufacturers falsely marketing these synthetic compounds as benign dietary supplements or herbal remedies.